ORGANIZATION

• JPMA Delays Announcement of Drug Pricing Proposal
  July 27, 2022

• JPMA Hails New Expert Panel, Plans to Raise “Drug Loss” Issue: Director General
  July 25, 2022

• Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
  July 15, 2022

• FPMAJ Lauds Ruling Bloc Election Win, Urges Drastic Social Security Debate
  July 12, 2022

• FPMAJ Chief Thanks Abe for AMED Launch, Vows to Carry On Innovative Drug Discovery
  July 12, 2022

• Regenerative Medicine Makers Have “Good Reasons” to Opt for Single-Wholesaler Route: FIRM Chair
  July 12, 2022

• JPMA Think Tank Finds Surge in Japan-Unapproved Drugs in Areas with High Unmet Needs
  July 12, 2022

• JPMA Committed to Building Drug Discovery Ecosystem: President
  July 5, 2022

• INES Launches Study Group to Propose Stable Healthcare Financing
  July 4, 2022

• Generic Use Rate Stands at 79.5% in FY2021: JGA
  June 30, 2022

• Kichiro Matsumoto Elected as New Chief of Japan Medical Association
  June 27, 2022

• Shipment Curbs Remain for Over 40% of Drugs Despite Sufficient Supply Volumes: FPMAJ Survey
  June 24, 2022

• JPMA Voices Major Disappointment with TRIPS Waiver Pact
  June 21, 2022

• Citizen’s Group Opposes Emergency Approval for Shionogi’s COVID Pill
  June 21, 2022

• It’s Time to Revise G1 Withdrawal Scheme, Rule Likely to Be Applied to Only a Few Products: FPMAJ
  June 14, 2022

• TRIPS Waiver Discussions Threaten Global Health Security: JPMA, IFPMA
  June 13, 2022

• FPMAJ Urges More Precise Handling of CEA Price Tweaks for Products with “Cost Increase” Profile
  June 13, 2022

• 4-Year Grace Period Was Good News, but More Should Be Done for Re-Pricing Exclusion: FPMAJ
  June 13, 2022

• FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
  June 13, 2022

• FPMAJ Drug Pricing Chief Renews Call for Fundamental Review of Off-Year Re-Pricing
  June 10, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• …
• Next ›
• 最終 »